Tools   Select Another Resource Report Type

http://www.oncotest.com/

A contract research organization (CRO) specializing in preclinical oncology services. As a pioneer in the field of patient derived tumor xenografts (PDX), they provide tailored solutions to the problems faced by preclinical oncology researchers. They assist with the identification of the best drug candidates and the validation of their targets and deliver in-depth bioinformatics analyses, laying the groundwork for the successful planning of clinical trials. Their diverse tumor model collection enables them to recommend the right assays and models to answer their customers' questions. Their AAALAC accredited facilities with IVC system, separate model development unit, large cage capacity of over 14,500 mice and proprietary electronic measurement system with an integrated database and by continuously maintaining important PDX models in mice, they are able to provide the highest standard of testing within a reasonable timeframe.

Proper citation: Oncotest (RRID:SCR_000489) Copy   

•   Source: SciCrunch Registry

http://sourceforge.net/projects/variantmaster/

Software program that extracts causative variants in familial and sporadic genetic diseases. The algorithm takes into account predicted variants (SNPs and indels) in affected individuals or tumor samples and utilizes the row (BAM) data to robustly estimate the conditional probability of segregation in a family, as well as the probability of it being de novo or somatic. In familial cases, various modes of inheritance are considered: X-linked, autosomal dominant, and recessive (homozygosity or compound heterozygosity). Moreover, it integrates phenotypes and genotypes, and employs Annovar to produce additional information as allelic frequencies in general population and damaging scores.

Proper citation: VariantMaster (RRID:SCR_000569) Copy   

•   Source: SciCrunch Registry

http://patchwork.r-forge.r-project.org/

Software tool for analyzing and visualizing allele-specific copy numbers and loss-of-heterozygosity in cancer genomes. The data input is in the format of whole-genome sequencing data which enables characterization of genomic alterations ranging in size from point mutations to entire chromosomes. High quality results are obtained even if samples have low coverage, ~4x, low tumor cell content or are aneuploid. Patchwork takes BAM files as input whereas PatchworkCG takes input from CompleteGenomics files. TAPS performs the same analysis as Patchwork but for microarray data.

Proper citation: Patchwork (RRID:SCR_000072) Copy   

•   Source: SciCrunch Registry

http://www.mycancergenome.org/

A freely available online personalized cancer medicine knowledge resource for physicians, patients, caregivers and researchers that gives up-to-date information on what mutations make cancers grow and related therapeutic implications, including available clinical trials. It is a one-stop tool that matches tumor mutations to therapies, making information accessible and convenient for busy clinicians.

Proper citation: My Cancer Genome (RRID:SCR_004140) Copy   

•   Source: SciCrunch Registry

http://www.proteinatlas.org/

Open access resource for human proteins. Used to search for specific genes or proteins or explore different resources, each focusing on particular aspect of the genome-wide analysis of the human proteins: Tissue, Brain, Single Cell, Subcellular, Cancer, Blood, Cell line, Structure and Interaction. Swedish-based program to map all human proteins in cells, tissues, and organs using integration of various omics technologies, including antibody-based imaging, mass spectrometry-based proteomics, transcriptomics, and systems biology. All the data in the knowledge resource is open access to allow scientists both in academia and industry to freely access the data for exploration of the human proteome.

Proper citation: The Human Protein Atlas (RRID:SCR_006710) Copy   

•   Source: SciCrunch Registry

http://ucneuroscience.com/

Leading treatment, research and teaching center for complex neurological conditions based at the University Hospital and the UC College of Medicine. Its physicians and researchers have created national models for evidence-based treatment and research of complex conditions, including ischemic and hemorrhagic stroke, brain aneurysms, brain and spinal cord trauma, brain tumors, Parkinson's disease, epilepsy and seizure disorders, multiple sclerosis, trigeminal neuralgia, Alzheimer's disease and memory disorders, mood disorders, and neuromuscular disorders. UCNI includes a team of more than 100 experts from 15 specialties who collaborate across disciplines to provide the most comprehensive diagnoses and treatments possible.

Proper citation: University of Cincinnati Neuroscience Institute (RRID:SCR_005345) Copy   

•   Source: SciCrunch Registry

http://ranchobiosciences.com/gse1456/

Curated series of expression data for 159 tumors from which RNA could be collected in sufficient amounts and quality for analysis from breast cancer patients. Tissue material was collected from all breast cancer patients receiving surgery at Karolinska Hospital from 1994-1996.

Proper citation: GSE1456 (RRID:SCR_003642) Copy   

•   Source: SciCrunch Registry

http://www.stanford.edu/~rnusse/pathways/targets.html

A list of target genes of Wnt/beta-catenin signaling. Suggestions for additions are welcome. Direct targets are defined as those with Tcf binding sites and demonstrating that these sites are important.

Proper citation: Target genes of Wnt/beta-catenin signaling (RRID:SCR_007022) Copy   

•   Source: SciCrunch Registry

https://www.jax.org/jax-mice-and-services/in-vivo-pharmacology/mouse-tumor-biology-database

Database supports use of mouse model system for human cancer by providing comprehensive resource for data and information on various tumor models.

Proper citation: Mouse Tumor Biology Database (RRID:SCR_006517) Copy   

•   Source: SciCrunch Registry

http://ercsb.ewha.ac.kr:8080/FusionGene/

Knowledgebase of fusion transcripts collected from various public resources such as the Sanger CGP, OMIM, PubMed, and Mitelman's database. It is an alignment viewer to facilitate examining reliability of fusion transcripts and inferring functional significance., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025.

Proper citation: ChimerDB (RRID:SCR_007596) Copy   

•   Source: SciCrunch Registry

https://www.urmc.rochester.edu/neurosurgery/specialties/neurooncology.aspx

Collaborative neuro-oncology research program with a tissue repository (tumor bank) containing a wide range of clinical specimens, which they make available to researchers in order to study the effects of new drugs on a large number and wide range of tumor specimens. They provide highly coordinated, complex care in neurosurgery, radiation oncology, medical oncology, and neurology to patients afflicted with tumors of the brain and spine by combining the newest technologies and treatments available anywhere in the world. The program is formed from a multidisciplinary group with a goal of helping patients navigate the complex issues surrounding brain and spinal cancer care. The researchers are working to increase the number of targets that could be considered for anti-angiogenesis therapy. Many of their studies focus on the blood vessel cells (endothelial cells) themselves, which, unlike tumor cells, rarely mutate and so might be less likely to become resistant to therapy and are also more easily reached through the bloodstream. Their researchers are also attempting to better understand the changes in the blood-brain barrier (BBB) that are associated with fluid accumulation and brain swelling (edema) in neuro-oncology patients. Normal brain tissue is shielded from the rest of the body by the BBB. This barrier is composed of very tight blood vessels that prevent most substances from entering the brain. Brain tumors have a leaky BBB ����?? this feature can be used to identify tumors on MRI scans. They have identified specific molecules that appear to be associated with the leaky, abnormal vessels while the normal blood vessels with intact BBB produce these molecules at very low levels or not at all. Inhibiting the function of these molecules may help control or prevent disruption of the BBB and limit cerebral edema in brain tumor patients, as well as patients suffering from stroke or traumatic brain injury.

Proper citation: University of Rochester Program for Brain Tumors and Spinal Tumors (RRID:SCR_005343) Copy   

•   Source: SciCrunch Registry

http://cancergenome.nih.gov/

Project exploring the spectrum of genomic changes involved in more than 20 types of human cancer that provides a platform for researchers to search, download, and analyze data sets generated. As a pilot project it confirmed that an atlas of changes could be created for specific cancer types. It also showed that a national network of research and technology teams working on distinct but related projects could pool the results of their efforts, create an economy of scale and develop an infrastructure for making the data publicly accessible. Its success committed resources to collect and characterize more than 20 additional tumor types. Components of the TCGA Research Network: * Biospecimen Core Resource (BCR); Tissue samples are carefully cataloged, processed, checked for quality and stored, complete with important medical information about the patient. * Genome Characterization Centers (GCCs); Several technologies will be used to analyze genomic changes involved in cancer. The genomic changes that are identified will be further studied by the Genome Sequencing Centers. * Genome Sequencing Centers (GSCs); High-throughput Genome Sequencing Centers will identify the changes in DNA sequences that are associated with specific types of cancer. * Proteome Characterization Centers (PCCs); The centers, a component of NCI's Clinical Proteomic Tumor Analysis Consortium, will ascertain and analyze the total proteomic content of a subset of TCGA samples. * Data Coordinating Center (DCC); The information that is generated by TCGA will be centrally managed at the DCC and entered into the TCGA Data Portal and Cancer Genomics Hub as it becomes available. Centralization of data facilitates data transfer between the network and the research community, and makes data analysis more efficient. The DCC manages the TCGA Data Portal. * Cancer Genomics Hub (CGHub); Lower level sequence data will be deposited into a secure repository. This database stores cancer genome sequences and alignments. * Genome Data Analysis Centers (GDACs) - Immense amounts of data from array and second-generation sequencing technologies must be integrated across thousands of samples. These centers will provide novel informatics tools to the entire research community to facilitate broader use of TCGA data. TCGA is actively developing a network of collaborators who are able to provide samples that are collected retrospectively (tissues that had already been collected and stored) or prospectively (tissues that will be collected in the future).

Proper citation: The Cancer Genome Atlas (RRID:SCR_003193) Copy   

•   Source: SciCrunch Registry

http://www.umassmed.edu/cancercenter/tissuebank/index.aspx

The UMass Cancer Center Tissue and Tumor Bank is a dynamic tissue procurement service: Collection, Storage, Annotation, and Distribution of Human Biologic Specimens. Our goal is to facilitate basic science, clinical research and translational studies by providing researchers with the ability to obtain and study human tissues using a dynamic collection, storage, annotation, and distribution service. * Fresh, diseased tissue is collected and processed immediately after surgery. ** When possible, surrounding healthy tissue is collected as a matched normal control. ** Anonymous, de-identified clinical and pathologic data are linked to the specimens in a secure database. * Bone marrow and blood specimens are collected and available as fresh cell isolates, frozen cell isolates or unprocessed. * A variety of services are available including routine histology, fresh tissue for cell culture, frozen sections, as well as DNA and RNA extraction. * Specific study needs can be met. * Consultation during study design is available and recommended. Contact Us * Assistance in the IRB approval process is offered. ** New: IRB approval is required only if you need identifiable private clinical information and/or patient follow-up for your study. The UMass Cancer Center Tissue and Tumor Bank is an open access biorepository. Specimens are available to investigators both internal and external to UMass. The Tumor Bank ships specimens to researchers worldwide. Please contact us to determine if we have specimens that meet your research needs.

Proper citation: UMass Cancer Center Tissue and Tumor Bank (RRID:SCR_004447) Copy   

•   Source: SciCrunch Registry

http://www.tubafrost.org/

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on January 9, 2023. In this web site you will find the central European database of OECI-TuBaFrost collecting the information of biobanks or in the project support environment on human material; i.e., frozen tumor tissue specimens, pathology blocks, blood samples in different forms, cell lines, Tissue Micro Arrays, etc. Our goal is by centralizing the tumor tissues information to facilitate the search of doctors / researchers for tumor materials, which they need for their cancer research there with facilitating cancer research. OECI members only can participate in the OECI-TuBaFrost exchange platform, or those introduced by an OECI member. We are a group of pathology and research departments as well as bio-bankers in clinical based biobanking based in comprehensive cancer centers or hospitals with a competence in comprehensive cancer care across Europe. Each participating institute is involved in cancer research resulting in innovative procedures, new drugs, improved diagnosis and new insights in disease development. The overall result is better care and treatment for cancer patients. To maximize the scientific value of the human tissue samples, information about the clinical status of the patient in combination with the quality and type of samples is very important. A TuBaFrost electronic database will securely store all this information. Within the closed project supporting environments, the data collected will include: * Diagnosis - identification of the type of cancer * Type of tissue collected - the origin, i.e. breast, skin, colorectal * Quality of tissue collected - collection and storage details The tissue is stored in the hospital where the donor was diagnosed/treated. It stays there until it is used or sent to another hospital or research center within the TuBaFrost group. The electronic database will track samples throughout the network. The tissue is not sold. The exchange of tissue to other hospitals is regulated by a contract, which uses the national regulations of the country supplying the tissue. Tissue samples within the TuBaFrost collection will only be used for research, which has been approved by ethics committees. This ensures that the tissue is only used for the best quality research and only for the specific reasons given to the ethics committee.

Proper citation: OECI - Tubafrost: The European Human Frozen Tissue Bank (RRID:SCR_004280) Copy   

•   Source: SciCrunch Registry

http://cancer.case.edu/sharedresources/tissue/

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on January 11, 2023. The Case Comprehensive Cancer Center''s Biorepository and Tissue Processing Core Facility (BTPC) serves two primary functions: 1. To build an inventory of remnant human tissues, blood and other body fluids (collectively termed biospecimens) targeted towards cancer and other medical research, for later assignment to investigators; and 2. To provide long term, controlled storage of biospecimens for specific researchers. These samples are for research purposes only and may not be used for clinical diagnosis or implantation into humans. Clinical information relating to the samples and donors are collected and maintained in a secure database. Samples and data are de-identified or de-linked before release to the researcher unless he/she has specific IRB approval to gain access to this information. Remnant biospecimens are prospectively collected from surgical procedures, autopsies and clinical laboratories for the BTPC by the Human Tissue Procurement Facility (HTPF), which operates under UH-IRB Protocol 01-02-45. Blood and bone marrow specimens are collected for the BTPC by the Hematopoietic Stem Cell Core Facility (HSCC), which operates under UH-IRB Protocol 09-90-195. The Division of Surgical Pathology at University Hospitals Case Medical Center (UHCMC) has clinical archives of paraffin blocks that can be made available through the BTPC for retrospective research studies under the approval of the Vice Chair for Clinical Affairs at UHCMC. Surgical Pathologists associated with the BTPC are responsible for determining which blocks can be made available and how much material can be removed from the blocks. Types of Tissue Available * Malignant, benign, diseased, normal and normal human tissues * Normal adjacent tissues available paired with tumor specimens in many cases * Tissues are collected from over 50 anatomic sites * Frozen specimens, OCT-embedded and paraffin-embedded tissues * Large array of paraffin-embedded specimens from clinical archives of paraffin blocks and QC research blocks maintained by the HTPF * Peripheral blood and bone marrow samples from initial visits and follow-up procedures are processed to obtain serum and cell fractions for storage * No samples are collected from individuals with known infectious illnesses * Fetal biospecimens are not collected due to state and local statutes

Proper citation: Case Comprehensive Cancer Center Biorepository and Tissue Processing Core Facility (RRID:SCR_004382) Copy   

•   Source: SciCrunch Registry

http://www.startthecure.com/clinical_tumor_bank.php

Biospecimen repository for tumor specimens, available to all researchers actively engaged in cancer research whether they are in University, Academic, or Pharmaceutical industry, with a goal to accelerate the discovery and development of new agents for the treatment and cure of cancer. The START tumor bank was created to make tumor tissue gifted by patients receiving care or treatment at The START Center available to all researchers involved in developing a better understanding of the biology of cancer or those engaged in the discovery of new therapies. The START Tumor Bank is a department within the PK Department and handles skin and tumor biopsies required by clinical trial protocols. A member of the PK Department is present during biopsy procedures for immediate processing of the sample for the trial. Additionally, the Tumor Bank collects and banks the tumor tissues of patients who consent. This tissue is then stored for future use by researchers developing new therapies.

Proper citation: START Tumor Bank (RRID:SCR_004258) Copy   

•   Source: SciCrunch Registry

https://htrn.osu.edu/Services/Biorepository/Pages/default.aspx

The HTRN biospecimen bank is comprised of samples for the Ohio State University Cancer and Leukemia Group B Pathology Coordinating Office (CALGB-PCO) and the Ohio State University Midwestern Division of the Cooperative Human Tissue Network (CHTN). The CALGB-PCO banks biospecimens donated by patients enrolled in clinical trials. Samples can include tumor and normal tissue, plasma, serum, whole blood and white blood cells and urine. All of these samples are used later in correlative studies. The Midwestern Division of the CHTN stores a temporary biospecimen bank of tumor and normal tissue, tissue slides and paraffin embedded tissue blocks for research investigators throughout the country and Canada who are trying to find a cure for cancer. As part of the HTRN biospecimen bank, a Rees Scientific equipment monitoring system helps to secure the integrity and quality of samples stored in the biorepository. Scientific research within the HTRN is currently underway to determine the best methods in tissue storage for long term use. The NCI First-Generation Guidelines for NCI-Supported Biorepositories and the NCI Best Practices for Biospecimen Resources are continuously reviewed and adapted by the HTRN.

Proper citation: Ohio State Biorepository (RRID:SCR_004714) Copy   

•   Source: SciCrunch Registry

https://conticabase.sarcomabcb.org/

This database contains anonymized information describing the tumor, treatment and follow-up as well as tumor sample availability and molecular biology analyses for mesenchymal tumors except GIST and bone tumors. The query tool allows users to ask questions about the overall content of the database in order to evaluate the feasibility of specific collaborative studies. We hope this database will become an important tool for increasing our knowledge on these rare tumors and for developing joint research programs. The tool can be used as a local center database thanks to its rules for access to patient data and material. Conticabase currently contains the following data from 31 out of the 48 registered centers (Last modification on 28/03/2012): * 11518 Patients * 11562 Tumors * 13897 Samples (13636 Paraffin and 5773 Frozen) Use of conticabase data At anytime, a data manager can export data of patients from his (her) Centre or group according to his (her) level of rights. To obtain data from another Centre, a partner should ask the coordinator of the corresponding Centre for these data. To use data for a cooperative study, a member should write a short text describing the project and send it to partners of interest. Each partner may decide whether to participate or not and therefore, whether to send or not the corresponding data to the project leader. In the event that the data from the conticabase result in a publication, acknowledgement is required. Use of tumour material entered in the ConticaBank To obtain material from another Centre for a cooperative study, a partner should write a short text describing the project and send it to the partners of interest. Each partner may decide whether to participate or not and, therefore, whether to send or not the corresponding material to the project leader. In the event that the material used result in a publication, acknowledgement is required.

Proper citation: Conticabase - European Sarcoma Database and Tumour Bank (RRID:SCR_004832) Copy   

•   Source: SciCrunch Registry

http://www.erasmusmc.nl/pathologie/clinicalpathology/tissuebank/161255/?lang=en

The Erasmus MC Virtual Tissue Bank is embedded in the department of Pathology. The collection is meant for medical research purposes only. This concerns a typical clinical based pathology biobank. Tissue samples left over from surgical resection specimen are stored under liquid nitrogen and can be requested by Erasmus MC scientists for medical scientific experiments. An application has been developed to enable scientists to search the collection on-line and request tissue samples over the Erasmus MC Intranet. Every request shall be judged according to procedures determined by the Erasmus MC Tissue Bank. A growing need is anticipated for large collections of well-diagnosed fresh frozen tumor tissue and, if available, corresponding pre-malignant and normal tissue samples. Scientific research on patient residual material has to comply with strict rules and regulations. Equipment The Erasmus MC Tissue bank manages the PALM microdissection laser for the center for Biomics, which is available through the center for Biomics ONLY after having followed an introduction course. Additionally, a complete TMA (Tissue Micro Array) platform, fully funded by the Josephine Nefkens Stichting, consisting of a Beecher Automated Tissue Arrayer ATA 27 and a Virtual Microscope or Nanozoomer from Hamamatsu and Medical Solutions with TMA analyses software strongly supports translational research on tissue samples. Complete histologic Images from the Virtual Microscope are available within the Erasmus MC Intranet or available on the Internet either by overview or a direct example.

Proper citation: Erasmus MC Tissue Bank (RRID:SCR_004945) Copy   

•   Source: SciCrunch Registry

http://www.clinicbiobanc.org/en_index.html

A biobank of repositories which works to obtain, store, manage and distribute large collections of human biological samples of phenotypes and diseases of marked interest for researchers. The biobank sample collection is made up of three extensive repositories. The Neurological Tissue Biobank is a nervous tissue repository (brain and spinal cord) created from donations from cadavers with or without neurological conditions. It helps facilitate research in neurological illnesses. The Tumour Biobank and Anatomical Pathologies Collections is a repository of tumorous tissue and samples from cancer patients. The Blood and Fluid Biobank is a repository which contains samples of metabolic, inflammatory bowel, hepatic, digestive and maternal and foetal diseases, among others. It houses a large range of samples of scientific interest, primarily DNA, serum and plasma.

Proper citation: Biobank of Hospital Clinic - IDIBAPS (RRID:SCR_004530) Copy   

•   Source: SciCrunch Registry